AI Drug Discovery 소프트웨어 시장 : 세계 예측(2026-2032년)

The AI Drug Discovery Software Market is projected to grow by USD 2.87 billion at a CAGR of 9.87% by 2032.

AI Drug Discovery Software: Executive Overview

AI drug discovery software applies machine learning, deep learning, generative models, knowledge graphs, and related computational methods to target identification, molecule design, virtual screening, biomarker discovery, and preclinical decision-making. Its role is expanding as pharmaceutical, biotechnology, academic, and public-sector researchers seek to process complex biological data more efficiently while improving the prioritization of experiments. Adoption depends on scientific validation, data quality, integration with laboratory workflows, regulatory confidence, cybersecurity, and access to specialized technical talent.

From Isolated Tools to Integrated Discovery Workflows

The landscape is shifting from standalone predictive applications toward connected platforms that link omics, structural biology, literature, clinical, and experimental data. Generative design is increasingly used alongside physics-based modeling, molecular simulation, and laboratory testing rather than as a replacement for them. These changes are also increasing the importance of interoperability, reproducibility, explainability, model governance, and human review. Organizations are placing greater emphasis on validating models against prospective experiments, documenting data provenance, and establishing controls for intellectual property and sensitive research information.

Artificial Intelligence Accelerates Prioritization, but Validation Remains Central

Artificial intelligence can help researchers identify patterns across high-dimensional datasets, rank candidate targets, propose molecular structures, predict selected properties, and automate portions of search and analysis. Its cumulative impact is strongest when models are connected to reliable experimental feedback, enabling iterative design-make-test-analyze cycles. Limitations remain significant: biased or incomplete training data, distribution shifts, uncertain biological mechanisms, weak transferability across assays, and difficulty reproducing results can reduce practical value. Accordingly, AI-generated outputs require domain expertise, laboratory confirmation, transparent performance evaluation, and appropriate oversight before they inform consequential development decisions.

Regional Insights: Adoption Reflects Research Capacity, Regulation, and Data Infrastructure

North America benefits from deep pharmaceutical, biotechnology, academic, cloud-computing, and venture ecosystems, while regulatory and data-governance expectations shape deployment. Europe emphasizes collaborative research, privacy, explainability, and alignment with evolving artificial-intelligence and health-data frameworks. Asia-Pacific combines strong capabilities in computational science, manufacturing, genomics, and pharmaceutical research, with adoption patterns varying across economies. Latin America is developing computational biology and biotechnology capacity, while infrastructure, funding continuity, and specialized skills influence implementation. The Middle East is investing in digital health, life sciences, and research infrastructure, with partnerships supporting capability building. Africa presents substantial opportunities in genomics, infectious-disease research, and locally relevant drug development, although connectivity, compute access, funding, and workforce development remain important considerations.

Group Insights: Cooperation Shapes Standards, Funding, and Deployment

ASEAN members are strengthening regional cooperation in digital health, biotechnology, and research capacity, but differ in infrastructure, regulation, and talent availability. BRICS countries bring substantial scientific, industrial, and population-scale data capabilities, while cross-border interoperability and governance remain complex. The European Union places strong emphasis on coordinated research, privacy, responsible AI, and common regulatory principles. G7 economies contribute advanced research institutions, pharmaceutical capabilities, computing resources, and policy discussions on trustworthy AI. GCC members are using coordinated investment and national transformation programs to develop life-science and digital capabilities. NATO countries span a broad research and security ecosystem, making data protection, resilience, dual-use awareness, and trusted collaboration relevant to deployment decisions.

Country Insights: Capabilities Are Uneven but Complementary

Australia combines strong medical research and university capabilities with opportunities in genomics and translational science. Brazil is developing biotechnology and computational research capacity while addressing infrastructure and data-access constraints. Canada benefits from established AI and life-science research communities and public research networks. China has extensive pharmaceutical, technology, and academic capabilities, with governance and cross-border data considerations shaping implementation. France, Germany, Italy, and Spain are supported by substantial research and healthcare ecosystems, while European data and AI requirements influence deployment. India offers a large technical workforce and growing biotechnology base, alongside varied infrastructure and validation capacity. Japan and South Korea combine advanced technology, manufacturing, and biomedical research capabilities. Mexico is strengthening biotechnology and research linkages. Russia retains scientific and technical capabilities, although collaboration, access, and regulatory conditions affect adoption. The United Kingdom has strong academic, biomedical, and regulatory expertise. The United States combines broad research, technology, pharmaceutical, and venture capabilities, with scrutiny focused on validation, data governance, and responsible use.

Action Priorities for Leaders Building Reliable AI Discovery Programs

Leaders should begin with clearly defined scientific and operational problems rather than adopting AI as an end in itself. They should establish governed data foundations covering provenance, consent, quality, access controls, and standardized representations; evaluate models using prospective, external, and decision-relevant validation; and connect software with laboratory automation and feedback loops where appropriate. Cross-functional teams should combine medicinal chemistry, biology, pharmacology, data science, engineering, regulatory, legal, and cybersecurity expertise. Organizations should also define model-risk tiers, human-approval checkpoints, documentation requirements, intellectual-property policies, vendor and interoperability criteria, and measurable outcomes such as experiment prioritization, reproducibility, cycle-time reduction, and scientific decision quality.

Research Methodology: Evidence-Led Assessment of the Software Landscape

This executive summary uses a qualitative, evidence-led framework for assessing AI drug discovery software. The analysis considers peer-reviewed scientific literature, regulatory and governmental publications, technical documentation, public research programs, industry disclosures, and established information on regional research and innovation systems. Findings are synthesized across application areas, enabling technologies, workflow integration, data governance, validation practices, infrastructure, talent, and policy conditions. Claims are limited to broadly documented structural trends; no market estimates, market sizing, market shares, forecasts, or company-specific comparisons are included. Regional, group, and country observations are interpreted in light of differences in research capacity, regulation, funding, computing access, and biomedical data infrastructure.

Conclusion: Scientific Validation and Trust Will Define Sustainable Adoption

AI drug discovery software is becoming an important layer in modern research workflows, particularly for organizing complex evidence, prioritizing experiments, and exploring chemical and biological possibilities. Its long-term contribution will depend less on novelty alone than on robust data practices, transparent evaluation, integration with experimental science, and responsible governance. Organizations that treat AI as a validated decision-support capability-supported by expert review, reproducible methods, secure infrastructure, and clear accountability-will be better positioned to translate computational advances into credible biomedical progress.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. AI Drug Discovery Software Market, by Component

• 7.1. Introduction
• 7.2. Professional Services
• 7.3. Software Platform
• 7.4. Support And Maintenance

8. AI Drug Discovery Software Market, by Ai Technology

• 8.1. Introduction
• 8.2. Computer Vision
• 8.3. Deep Learning
  • 8.3.1. Convolutional Neural Networks
  • 8.3.2. Generative Adversarial Networks
  • 8.3.3. Recurrent Neural Networks
• 8.4. Machine Learning
  • 8.4.1. Reinforcement Learning
  • 8.4.2. Supervised Learning
  • 8.4.3. Unsupervised Learning
• 8.5. Natural Language Processing

9. AI Drug Discovery Software Market, by Therapeutics Area

• 9.1. Introduction
• 9.2. Cardiovascular
• 9.3. Cns
• 9.4. Infectious Diseases
• 9.5. Oncology

10. AI Drug Discovery Software Market, by End User

• 10.1. Introduction
• 10.2. Academic And Research Institutes
• 10.3. Biotechnology Companies
• 10.4. Contract Research Organizations
• 10.5. Pharmaceutical Companies

11. AI Drug Discovery Software Market, by Deployment Mode

• 11.1. Introduction
• 11.2. Cloud
  • 11.2.1. Private Cloud
  • 11.2.2. Public Cloud
• 11.3. Hybrid
• 11.4. On-Premises

12. AI Drug Discovery Software Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. AI Drug Discovery Software Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. AI Drug Discovery Software Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Absci Corp.
• 16.2. Atomwise, Inc.
• 16.3. BenevolentAI Limited
• 16.4. BioSymetrics Corp.
• 16.5. Cloud Pharmaceuticals, Inc.
• 16.6. Cyclica Inc.
• 16.7. Exscientia plc
• 16.8. Gritstone bio, Inc.
• 16.9. Insilico Medicine, Inc.
• 16.10. Owkin, Inc.
• 16.11. Recursion Pharmaceuticals, Inc.
• 16.12. Schrodinger, Inc.
• 16.13. Sensyne Health plc

17. Key Experts